Nabla Names New CEO

Nabla’s leadership change is a healthtech signal rather than a funding event, but it matters because the company sits in one of AI’s most commercially sensitive markets.

What happened

Paris-based AI healthtech company Nabla named Brian Manning as CEO, six months after Alexandre Lebrun’s departure.

Nabla is known for AI tools used in clinical workflows, including documentation and support for healthcare professionals. The CEO transition now raises the question of how the company will prioritise growth, enterprise adoption and product focus in a market where trust and clinical workflow fit are critical.

Why it matters

Healthcare AI is not like consumer AI. Adoption depends on safety, reliability, procurement, regulation and whether clinicians actually want the tool inside their daily work.

A leadership reset can therefore signal more than internal management change. It can shape sales strategy, product positioning and whether a company leans toward platform-building, deeper hospital adoption or partnership routes.

The bigger picture

Europe has produced several visible AI healthtech companies, but scaling them remains difficult. Nabla’s next phase will be a test of whether clinical AI tools can move from promising pilots into durable healthcare infrastructure.